Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis

•This NMA aimed to evaluate the efficacy and safety of six new antiseizure medications (ASMs) for focal epilepsy, Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC). This NMA indicated that the most effective treatment strategy for focal epilepsy, DS, Lennox–Gastaut syndrome, and TSC, respectively, included CBM 300 mg, FFM, CBD, and ELM. However, the aforementioned findings need further confirmation.